74 results about "Increased cholesterol" patented technology

Antibody capable of mediating effector function which specifically binds to a multiple membrane spanning antigen or to an antigen which forms dimers or multimers (i) for use in combination with a cholesterol-increasing agent in the treatment of a disease or disorder associated with said antigen, wherein antibody-induced effector function has a beneficial effect on said disease or disorder or (ii) for use in the treatment of such disease or disorder, wherein the antibody is to be administered to a subject undergoing therapy with a cholesterol-lowering agent, such as a statin, and wherein the subject is withdrawn from treatment with the cholesterol-lowering agent prior to the administration of the antibody. Furthermore, a kit of parts comprising such antibody as well as a cholesterol-increasing agent.

The invention provides a composition and a method for lowering blood serum cholesterol levels or for preventing elevated blood serum cholesterol levels, as well as suitable composition comprising (a) one or more phytosterols and / orphytostanols or a mixture thereof capable of reducing cholesterol absorption in the intestine, (b) a composition capable of inhibiting cholesterol biosynthesis, and (c) a composition capable of increasing cholesterol metabolism, wherein at least one of compositions b. and c. is preferably derived from plants.

The present invention relates to methods for prevention and / or treatment of metabolic disorders, post-menopausal obesity and conditions associated with high fat diet consumption including, obesity, body weight gain, fat mass formation, bone mineral content reduction, white adipose tissue weight gain, increased cholesterol levels, increased leptin levels, insulin resistance, type II diabetes, increased blood glucose levels, inflammatory diseases, cardiovascular diseases, fatty liver condition (accumulation of fat in the liver), decreased uncoupling protein-1 (UCP-1) levels and increased lipogenesis.

The present invention relates to compounds of the formulawherein A1, A2, A3 and R1 to R8 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and / or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.

The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear steroid metabolite that increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and / or triglycerides. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and / or high triglycerides (e.g. hypercholesterolemia, hyperlipidemia, and atherosclerosis) are also provided.

The present invention relates to pyrazine derivatives of the formulaand pharmaceutically acceptable salts thereof, wherein R1 to R8 are as defined in the description and claims for use as HDL-cholesterol raising agents in the treatment and / or prophylaxis of diseases or disorders that can be treated with such agents such as dyslipidemia.

The invention relates to a preparation method of peanut wire-drawing protein. The preparation method comprises the following steps: 1) preparing low-denaturalization peanut protein powder; 2) mixing uniformly; 3) hardening and tempering; 4) extruding and swelling; and 5) discharging. The product of the invention is pure white and has specific peanut aroma and rapid rehydration; when the product is torn, a structure as thin as hair can be formed; and moreover, the product has an obvious fibrous tissue, high fiber toughness, tensile force and elasticity, forms a ball without breakage when kneaded by hands, and disperses like fiber immediately after rehydration. The peanut wire-drawing protein ensures that the nutrition level of people is improved without increasing cholesterol, has a uniqueflavor without beany flavor or flatulence factor of soy protein, and is a high-quality resource of vegetable protein. Meanwhile, a proper amount of soy protein and wheat protein is added, and the three high-quality vegetable proteins are combined so that the allocation of essential amino acids for human contained in the peanut wire-drawing protein is more reasonable and better conforms to the nutrition requirements of the human.

The invention provides a composition and a method for lowering blood serum cholesterol levels or for preventing elevated blood serum cholesterol levels, as well as a suitable composition comprising (a) one or more phytosterols and / or phytostanols capable of reducing cholesterol absorption in the intestine and / or one or more soluble fibres capable of inhibiting ileal bile acid absorption, (b) a composition capable of inhibiting cholesterol biosynthesis, and (c) a composition capable of increasing cholesterol metabolism, wherein at least one of compositions (b) and (c) is preferably derived from plants.

The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and / or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and / or high triglycerides and / or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.

The invention relates to a nutritious compound protein powder, which eliminates the defect that the present food which is used to supplement protein can increase the risk of cardiovascular disease because of the increase of fat and cholesterol. The compound protein powder includes 8-12 shares (by weight) human collagen protein, 8-12 shares (by weight) bovine coloctrum, 250-350 shares (by weight) soybean protein and 550-650 shares (by weight) whey protein.

The invention provides application of mannuronic acid oligomers in preparing medicines, health products or dietary supplements for preventing and treating alcoholic liver injury. Mannuronic acid oligomers with different molecular weights, which are obtained by degrading polymannuronic acid graded and purified from algin, can lower the hepatosomatic index increase caused by alcoholic injury, resist triglyceride and cholesterol increase caused by alcohol, effectively lower glutamic-pyruvic transaminase and glutamic oxaloacetic transaminase increase in serum caused by alcohol, enhance the total oxidation resistance and glutathione level of the serum, lower the mouse drunkenness rate, prolong the mouse drunkenness time, and shorten the sober-up time, thereby implementing the protective action and hangover alleviating function on alcoholic hepatic injury. The products provided by the invention are derived from marine natural products, have the advantages of abundant resources, high industrialization tendency, high safety, high effectiveness and the like, and have wide development and application prospects in the aspects of prevention and treatment of alcoholic hepatic injury, hangover alleviation and liver protection.

Methods and compositions useful for preventing the disruption of thiol (sulfur) signaling which affects degenerative / age related disease and other disease states related to thiol redox signaling, such as S-glutathiolation. The compositions are capable of increasing the DNA transcription of Gamma-Glutamyl-cysteine synthase which is the rate limiting enzyme for the production of the thiol regulating enzyme Glutathione. The acid-stable compositions disclosed herein contain esterfied and free form cafestol and kahweol, and may be formed using ground roasted or unroasted coffee beans. The beans in combination with water are exposed to cavatonic energy sonic or mechanical. C&K typically increase cholesterol and damage the liver. The compositions disclosed are absorbed before or after the distal portion of the small intestines, eliminating liver toxicity and increases in cholesterol. Additional materials may be added to the compositions, such as additional hydrophobic compounds hydrophilic compounds, and may be added to the film or embedded in the compositions by the cavitation process. The process is also adapted for use in all standard methods of brewing coffee, causing the coffee to possess the disclosed compositions.

The present invention relates to a method of raising HDL cholesterol comprising administering to a patient in need thereof a compound of the formula wherein A, G, R1 to R8 and R17 are as defined in the description.

The invention provides application of guluronic acid oligomers in preparing medicines, health products or dietary supplements for preventing and treating alcoholic liver injury. Guluronic acid oligomers with different molecular weights, which are obtained by degrading polyguluronic acid graded and purified from algin, can lower the hepatosomatic index increase caused by alcoholic injury, resist triglyceride and cholesterol increase caused by alcohol, effectively lower glutamic-pyruvic transaminase and glutamic oxaloacetic transaminase increase in serum caused by alcohol, enhance the total oxidation resistance, glutathione level and superoxide dismutase activity in the serum, inhibit the generation of malonaldehyde in the liver caused by alcohol, lower the mouse drunkenness rate, prolong the mouse drunkenness time, and shorten the sober-up time, thereby implementing the protective action and hangover alleviating function on alcoholic hepatic injury. The products provided by the invention are derived from marine natural products, have the advantages of abundant resources, high industrialization tendency, high safety, high effectiveness and the like, and have wide development and application prospects in the aspects of prevention and treatment of alcoholic hepatic injury, hangover alleviation and liver protection.

This invention provides methods to predict the degree of elevation of serum cholesterol levels in patients treated with immunosuppressive medication. This invention also provides treatment strategies based on these predictions and kits to carry out these methods.

A rice bran-like composition having higher bioactivity is provided by modifying rice bran. A rice bran-like composition contains a mixture of (1) defatted rice bran obtained by pressing rice bran to remove oil and (2) rice bran oil obtained by refining pressed rice bran oil, wherein a weight ratio of defatted rice bran content to rice bran oil content is 85:15 to 60:40. A food contains (1) defatted rice bran and (2) rice bran oil in a weight ratio of 85:15 to 60:40. Preferable components of the rice bran-like composition are as follows: the fat content is 20 to 40 wt. %, the protein content is 10 to 17 wt. %, the carbohydrate content is 5 to 21 wt. %, the ash content is 7 to 13 wt. %, and the fiber content is 20 to 32 wt. %. The present invention provides an effect of reducing or suppressing an increase in visceral fat; an effect of reducing or suppressing an increase in neutral fat in blood; and an effect of reducing or suppressing an increase in blood cholesterol, all the effects being superior to those of rice bran.

A peroxisome proliferator activated receptor regulator containing a carboxylic acid derivative of formula (I) (wherein all symbols are as defined in the specification), a non-toxic acid thereof or a hydrate thereof as active ingredient.Because of having an effect of regulating PPAR, a compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive and / or a remedy for diseases associating metabolic disorders (diabetes, obesity, syndrome X, hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipemia, atherosclerosis, hypertension, circulatory diseases, overeating, coronary heart diseases, etc., an HDL cholesterol-elevating agent, an LDL cholesterol and / or VLDL cholesterol-lowering agent and a drug for relief from risk factors of diseases or syndrome X.

The invention discloses semen cassiae health oral liquid. The semen cassiae health oral liquid is prepared from the following raw materials in parts by weight: 10 to 50 parts of semen cassiae, 10 to 20 parts of oriental wormwood, 10 to 20 parts of cattail pollen, 10 to 20 parts of the root of red-rooted salvia, 10 to 20 parts of rhizome of rehmannia, 10 to 20 parts of scutellaria baicalensis, 10 to 20 parts of radices trichosanthis, 10 to 20 parts of gynostemma pentaphylla, 10 to 20 parts of the pod of a pagoda tree, 10 to 20 parts of pericarpium citri reticulatae, 10 to 20 parts of polygonum cuspidatum, 10 to 20 parts of rhizoma alismatis, 10 to 20 parts of hawthorn, 10 to 20 parts of prepared fleece flower root, 10 to 20 parts of rhizoma atractylodis macrocephalae, 10 to 20 parts of stigma of corn, 10 to 20 parts of tribulus terrestris, and 10 to 20 parts of lysimachia christinae hance. According to the semen cassiae health oral liquid, semen cassiae mainly contains phytosterol and anthraquinone substances which can inhibit the increase of serum cholesterol as well as inhibiting atherosclerotic plaque, and the blood lipid decreasing effect is obvious; the semen cassiae is bitter and inconvenient to take; the semen cassiae is prepared into oral liquid and added with medicinal materials capable of promoting blood circulation to remove blood stasis, and the medicinal materials are mild in taste and easily accepted by people, so that the effect of decreasing the blood lipid can be achieved well.

The miRNA miR-33 is shown to inhibit the expression of carnitine O-octaniltransferase (CROT), Carnitine palmitoyltransferase 1A (CPT1a) and hydroxyacyl-CoA-dehydrogenase (HADHB), reduce fatty acid oxidation in hepatic cells, and target the insulin receptor substrate 2 (IRS-2) independent of its ability to elevating plasma high density lipoprotein (HDL) levels. MiR-33 inhibitors are also shown to increase cholesterol efflux from peripheral cells, such as cholesterol-laden macrophages present in atherosclerotic plaques. Compositions and methods are therefore provided for treating or preventing metabolic syndrome and atherosclerosis using miR-33 inhibitors. The miR-33 inhibitors are preferably antagomirs having a single-stranded nucleic acid sequence that is complementary to at least 12 contiguous nucleotides in miR-33 and therefore forms a duplex with miR-33 under physiological conditions.

The present invention relates to a method of raising HDL cholesterol comprising administering to a patient in need thereof a compound of the formulawherein A, G, R1 to R8 and R17 are as defined in the description.

The present invention relates to compositions for use and formulation as weight management products and in particular fermented dairy foodstuffs. The compositions generally comprise two or more of the following components: a) a microbiome modifying component; b) a satiety modifying component; and c) a metabolic modifying 5 component and at least one of the following: d) Streptococcus thermophilus CBS 139100 and Lactobacillus delbrueckii subsp. bulgaricus CBS 139099 microbial strains or mutant strains or fragments or fractions thereof; e) a combination of Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus microbial strains which together, or individually, are capable of secreting polysaccharides having high levels of galactosamine 10 and no or low levels of rhamnose and glucuronic acid when grown on a dairy substrate; or f) polysaccharides formed of: i) 15-25% galactosamine; ii) 45-60% galactose; and iii) 20-30% glucose. The compositions may also be useful in the management or treatment of obesity, elevated cholesterol, diabetes, hypertension or heart disease.

Fatty acid conjugates of salicylate derivatives and compositions thereof are disclosed. Further disclosed are methods for treating and / or preventing an inflammatory disease including inflammation and / or inflammatory bowel disease (IBD), dyslipidemia including mixed dyslipidemia and / or hypertriglyceridemia, elevated blood lipids including, e.g., triglycerides and / or cholesterol, metabolic syndrome, peripheral insulin resistance, diabetes, atherosclerosis; a method for lowering non-HDL cholesterol; and a method for raising HDL-cholesterol comprising the administration of an effective amount of at least one compound according to the present disclosure.

The invention discloses a lipid-lowering and gallbladder-dredging capsule and belongs to the technical field of traditional Chinese medicine prescriptions. The capsule is prepared from nine types of traditional Chinese medicinal materials, namely radix bupleuri, oriental wormwood, longhairy antenoron herbs, radix et rhizome rhei, rhizoma corydalis, curcuma aromatic, etc. Compatibility of all the medicinal materials is achieved, and the effects of soothing the liver, strengthening the spleen, promoting the circulation of blood and qi, dredging the gallbladder and relieving pain are achieved; the capsule is applicable to costalgia and gallbladeer swelling caused by heat toxin accumulation and lung-qi obstruction, and the symptoms are assistant rib swelling pain, fever, yellow urine and constipation. Through biochemical detection, it is found that triglyceride is raised, and cholesterol is raised. Ultrasonic detection shows that liver light spots are thickened and increased; the capsule is used for treating cholecystitis, gallstones, fatty liver, coronary disease, cerebral thrombosis, hypertension and hyperlipermia. The capsule is clinically applied for more than ten years and well received by patients due to the remarkable treatment effect. The capsule is a pure traditional Chinese medicine capsule preparation obtained through experimental research and development conducted on powder, the capsule is high in content of medicinal compositions, accurate in dosage, reliable in effect and fast in in-vivo disintegration, dispersion, absorption and effect achieving. Production equipment is simple, and the capsule is suitable for mass production to meet the market demand.

The invention provides steamed buns with an assistant effect of reducing blood fat and cholesterol. The steamed buns comprise the following raw materials: flour, Chinese medicine additives, water, honey and yeast. The Chinese medicine additives used in the steamed buns comprise the following bulk drugs: cattail pollen, evening primrose, fruit of Cherokee rose, turmeric, hawthorn, fruit of glossy privet, giant knotweed, pseudo-ginseng, radix astragali, cassia seeds, roots of red-rooted salvia, ligusticum wallichii, rheum officinale, rhizoma alismatis, radix paeoniae rubrathe, lotus leaves, waxgourd peel and oriental wormwood. The regimen is far different from a method of taking bitter medicines, the steamed buns are different from the medicines which are difficult to take, patients difficultly persist in taking the medicines, but the steamed buns can be easily accepted by the patients, the patients can eat the steamed buns day by day, and the steamed buns are particularly suitable for conditioning and treating chronic diseases. The cassia seeds in the bulk drugs taste sweet and bitter, are cold in nature, have effects of clearing liver, improving vision, suppressing liver-yang and reducing serum cholesterol, have good curative effect on prevention and treatment of vascular hardening, have a hepatoprotective effect, and can suppress cholesterol increasing and formation of aorta atheromatous plague.

Novel amino acid derivatives are provided that are useful for management of disorders such as obesity and immunological diseases. The derivatives are also useful in lowering blood glucose levels in hyperglycemic disorders and for treating related disorders such as body weight gain, elevated free fatty acid, cholesterol and triglyceride levels and other disorder exacerbated by obesity.

The miRNA miR-33 is shown to inhibit the expression of carnitine O-octaniltransferase (CROT), Carnitine palmitoyltransferase 1A (CPT1a) and hydroxyacyl-CoA-dehydrogenase (HADHB), reduce fatty acid oxidation in hepatic cells, and target the insulin receptor substrate 2 (IRS-2) independent of its ability to elevating plasma high density lipoprotein (HDL) levels. MiR-33 inhibitors are also shown to increase cholesterol efflux from peripheral cells, such as cholesterol-laden macrophages present in atherosclerotic plaques. Compositions and methods are therefore provided for treating or preventing metabolic syndrome and atherosclerosis using miR-33 inhibitors. The miR-33 inhibitors are preferably antagomirs having a single-stranded nucleic acid sequence that is complementary to at least 12 contiguous nucleotides in miR-33 and therefore forms a duplex with miR-33 under physiological conditions.

The present invention is related to a novel food intermediate containing a phytosteryl esters complex and the method used to create the food intermediate. The food product provides beneficial hypocholesterolemic activity through increased cholesterol-uptake inhibition while simultaneously delivering a food product that is not adversely affected by its inclusion, either in taste or texture or in any undesirable side effects.

The invention discloses sugar-free Jiangzhining grains. The traditional Chinese medicine is prepared from the following raw materials in parts by weight: 20 to 25.5 parts of fructus crataegi, 1 to 1.25 parts of radix polygonum multiflorum preparata, 1 to 1.25 parts of semen cassiae, and 3.25 to 3.55 parts of lotus leaf. The sugar-free Jiangzhining grains provided by the invention have the effects of dilating coronary vessels, increasing coronary blood flow, reducing cholesterol absorption, accelerating cholesterol excretion, inhibiting serum cholesterol increase and atherosclerotic plaque formation, reducing blood fat and cholesterol, and the like. The sugar-free Jiangzhining grains are more suitable for middle-aged and elderly diabetic patients, and the application range of the grains is enlarged.